Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
179M
-
Number of holders
-
112
-
Total 13F shares, excl. options
-
66.7M
-
Shares change
-
+18M
-
Total reported value, excl. options
-
$467M
-
Value change
-
+$126M
-
Put/Call ratio
-
1.15
-
Number of buys
-
60
-
Number of sells
-
-42
-
Price
-
$7.00
Significant Holders of Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) as of Q1 2024
126 filings reported holding PRME - Prime Medicine, Inc. - Common Stock, $0.00001 par value as of Q1 2024.
Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) has 112 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.7M shares
of 179M outstanding shares and own 37.3% of the company stock.
Largest 10 shareholders include Alphabet Inc. (15.1M shares), ARK Investment Management LLC (5.99M shares), VANGUARD GROUP INC (5.8M shares), FMR LLC (3.92M shares), BlackRock Inc. (3.76M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.36M shares), Nikko Asset Management Americas, Inc. (3.36M shares), T. Rowe Price Investment Management, Inc. (3.09M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.52M shares), and Redmile Group, LLC (2.07M shares).
This table shows the top 112 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.